Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

More Evidence of Link Between Severe Gum Disease and Cancer Risk
March 2, 2018
Cancer, the Flu, and You
March 5, 2018
Show all

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.

“Biogen believes the voluntary worldwide withdrawal of ZINBRYTA, a treatment for relapsing multiple sclerosis, is in the best interest of patients,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “Biogen and AbbVie continue to prioritize patient safety and the care of multiple sclerosis patients worldwide.”

Biogen will continue to work collaboratively with regulatory authorities in the withdrawal of product and with healthcare providers worldwide in their support of ZINBRYTA patients.

Patients currently treated with ZINBRYTA should contact their healthcare provider if they have any questions or concerns.

Read Full Release: http://media.biogen.com/press-release/autoimmune-diseases/biogen%C2%A0and-abbvie-announce%C2%A0-voluntary%C2%A0worldwide-withdrawal-marketi

 

 

 

Comments are closed.